Showing results (371-380 of 855) with videos related to
Sort By:
Pageof 86
Frontiers in Pharmacology|September 19, 2022
Sexual dimorphic response to rituximab treatment: A longitudinal observational study in a large cohort of patients with primary membranous nephropathy and persistent nephrotic syndromeAnnalisa Perna, Barbara Ruggiero, Manuel Alfredo Podestà, et al.Journal of the American Society of Nephrology : JASN|October 29, 2014
Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKDGerald Schulman, Tomas Berl, Gerald J Beck, et al.Journal of the American Society of Nephrology : JASN|April 9, 2016
Determining the Optimal Protocol for Measuring an Albuminuria Class Transition in Clinical Trials in Diabetic Kidney DiseaseTobias F Kröpelin, Dick de Zeeuw, Giuseppe Remuzzi, et al.Kidney International|August 8, 2002
Effect of angiotensin II antagonism on the regression of kidney disease in the ratAndrea Remuzzi, Elena Gagliardini, Chiara Donadoni, et al.Lancet (London, England)|March 7, 2002
Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomised trialRaul Plata, Arturo Cornejo, Carla Arratia, et al.American Journal of Nephrology|August 31, 2011
Antiproteinuric effect of chemokine C-C motif ligand 2 inhibition in subjects with acute proliferative lupus nephritisAlessandro Ble, Marta Mosca, Giorgio Di Loreto, et al.Journal of the American Society of Nephrology : JASN|October 7, 2004
Targeted deletion of angiotensin II type 1A receptor does not protect mice from progressive nephropathy of overload proteinuriaAriela Benigni, Daniela Corna, Carla Zoja, et al.Clinical and Experimental Nephrology|July 26, 2017
Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120Gerald Schulman, Tomas Berl, Gerald J Beck, et al.Arthritis and Rheumatism|May 1, 2007
Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupusCarla Zoja, Federica Casiraghi, Sara Conti, et al.BMC Nephrology|October 8, 2016
The effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trialsGerald Schulman, Tomas Berl, Gerald J Beck, et al.Pageof 86